Giordano Madeddu1, Hilde Vroling2, Anouk Oordt-Speets2, Sergio Babudieri3, Éamonn O'Moore4, Marije Vonk Noordegraaf2, Roberto Monarca5, Pier Luigi Lopalco6, Dagmar Hedrich7, Lara Tavoschi8. 1. Department of Medical, Surgical and Experimental Sciences, Unit of Infectious Diseases, University of Sassari, Sassari, Italy. Electronic address: giordano@uniss.it. 2. Pallas Health Research and Consultancy B.V., Rotterdam, the Netherlands. 3. Department of Medical, Surgical and Experimental Sciences, Unit of Infectious Diseases, University of Sassari, Sassari, Italy. 4. Health and Justice Team, Public Health England and UK Collaborating Centre, WHO Health in Prisons Programme (Europe), Reading, United Kingdom. 5. Health Without Barriers - European Federation for Prison Health, Viterbo, Italy. 6. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. 7. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal. 8. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; European Centre for Disease Prevention and Control, Stockholm, Sweden.
Abstract
INTRODUCTION: In 2016, more than 600,000 persons were being held in EU/EEA correctional facilities on a given day. People in prison may be at risk of vaccine-preventable diseases. While vaccination recommendations for people in prison exist, little is known on coverage and implementation options. METHODS: We performed a systematic review on existing evidence on vaccination in prison settings in the EU/EEA. We searched peer-reviewed and grey literature following international methodology and reporting standards, to gather records published between 1980 and 2016 in all languages. We analysed quantitative (acceptance, uptake, cost-effectiveness) and qualitative (barriers) outcomes. RESULTS: Out of 7041 identified records, 19 full-text articles were included from peer-reviewed literature and two from grey literature. Of these, 18 reported on hepatitis A and/or B virus (HAV/HBV), two on influenza and one on MMR vaccination. Two studies on HAV vaccine reported varying acceptance (5-91%) and uptake rates (62.9-70.5%). Seven studies reported on HBV vaccination. A comparative study showed a significantly higher uptake of the third HBV vaccine dose with the very rapid (63%) compared to the standard schedule (20%). HBV vaccination was generally well accepted (54-100%), whereas uptake was variable (dose 1:23-100%, dose 2:48-92%, dose 3:19-80%). One study on the combined HAV/HBV vaccine reported an acceptance rate of 34%, and declining uptake following dose 1. One study on influenza vaccine showed an uptake of 42-46%, while another reported a MMR vaccine acceptance of 80% and an uptake of 74%. Overall, main reasons for non-vaccination included release from/or transfer between prisons, and refusal. CONCLUSIONS: This systematic review highlighted important knowledge gaps and operational challenges for vaccination in prison settings. Vaccination is an effective measure that warrants comprehensive and tailored implementation to reduce the preventable disease burden, avoid risks of large outbreaks of vaccine-preventable diseases, and contribute to health equity for people in prison. Crown
INTRODUCTION: In 2016, more than 600,000 persons were being held in EU/EEA correctional facilities on a given day. People in prison may be at risk of vaccine-preventable diseases. While vaccination recommendations for people in prison exist, little is known on coverage and implementation options. METHODS: We performed a systematic review on existing evidence on vaccination in prison settings in the EU/EEA. We searched peer-reviewed and grey literature following international methodology and reporting standards, to gather records published between 1980 and 2016 in all languages. We analysed quantitative (acceptance, uptake, cost-effectiveness) and qualitative (barriers) outcomes. RESULTS: Out of 7041 identified records, 19 full-text articles were included from peer-reviewed literature and two from grey literature. Of these, 18 reported on hepatitis A and/or B virus (HAV/HBV), two on influenza and one on MMR vaccination. Two studies on HAV vaccine reported varying acceptance (5-91%) and uptake rates (62.9-70.5%). Seven studies reported on HBV vaccination. A comparative study showed a significantly higher uptake of the third HBV vaccine dose with the very rapid (63%) compared to the standard schedule (20%). HBV vaccination was generally well accepted (54-100%), whereas uptake was variable (dose 1:23-100%, dose 2:48-92%, dose 3:19-80%). One study on the combined HAV/HBV vaccine reported an acceptance rate of 34%, and declining uptake following dose 1. One study on influenza vaccine showed an uptake of 42-46%, while another reported a MMR vaccine acceptance of 80% and an uptake of 74%. Overall, main reasons for non-vaccination included release from/or transfer between prisons, and refusal. CONCLUSIONS: This systematic review highlighted important knowledge gaps and operational challenges for vaccination in prison settings. Vaccination is an effective measure that warrants comprehensive and tailored implementation to reduce the preventable disease burden, avoid risks of large outbreaks of vaccine-preventable diseases, and contribute to health equity for people in prison. Crown
Authors: David Lessard; David Ortiz-Paredes; Hyejin Park; Olivia Varsaneux; James Worthington; Nicole E Basta; Shannon E MacDonald; Bertrand Lebouché; Joseph Cox; Shainoor J Ismail; Nadine Kronfli Journal: Vaccine X Date: 2022-02-19
Authors: Yiran E Liu; Jillian Oto; John Will; Christopher LeBoa; Alexis Doyle; Neil Rens; Shelley Aggarwal; Iryna Kalish; Marcela Rodriguez; Beruk Sherif; Chrisele Trinidad; Michael Del Rosario; Sophie Allen; Robert Spencer; Carlos Morales; Alexander Chyorny; Jason R Andrews Journal: Prev Med Rep Date: 2022-03-15
Authors: Nancy Vicente-Alcalde; Jose Tuells; Cecilia M Egoavil; Esther Ruescas-Escolano; Cesare Altavilla; Pablo Caballero Journal: Int J Environ Res Public Health Date: 2020-10-31 Impact factor: 3.390
Authors: Nancy Vicente-Alcalde; Esther Ruescas-Escolano; Zitta Barrella Harboe; José Tuells Journal: Int J Environ Res Public Health Date: 2020-10-19 Impact factor: 3.390